IJCRR - Vol 07 Issue 16, August, 2015
HEPATITIS C VIRUS: SCREENING, DIAGNOSIS, AND INTERPRETATION OF LABORATORY ASSAYS
Author: Amit H. Agravat, Mital J. Gamit, Gauravi A. Dhruva, Kaushal R. Bhojani, Krupal M. Pujara
Background: All blood and blood products should be tested for Hepatitis C virus (HCV) before transfusion to decrease prevalence
Aim and Objective: The aim of present study is to determine the prevalence of hepatitis c virus (HCV) and to check the accuracy
of our laboratory analysis used for HCV testing of blood donors in our blood bank.
Material and Methods: The duration of this study is of 2 year since April 2013 to March 2015. All donors are screened during
counselling. The blood sample of Total Donor 26,789 including voluntary and replacement were tested for anti HCV antibody by
3 rd generation ELISA (QUALISA).Samples which are reactive or in gray zone were retested by ELISA and also confirmed by
rapid HCV card.
Results: From total donor 26,789, positive for the HCV were 45 (0.16%). Out of 45, 42 (93.3%) were male, 3(6.6 %,) were female
positive. 25 (55.5%) were voluntary and 20 (44.4%) were replacement. Maximum donors come under the age group of
21-30 and 31 -40 and 22 (48.8%) were B RhD positive subjects found.
Conclusion: The prevalence of HCV infection is mild (0.16 %) in blood donors in blood bank of PDU medical college and hospital,
Rajkot. The prevalence is equal in voluntary and replacement donors. Males are more infective than female.
Keywords: HCV infection, Anti HCV antibody, Blood donors
Amit H. Agravat, Mital J. Gamit, Gauravi A. Dhruva, Kaushal R. Bhojani, Krupal M. Pujara. HEPATITIS C VIRUS: SCREENING, DIAGNOSIS, AND INTERPRETATION OF LABORATORY ASSAYS International Journal of Current Research and Review. Vol 07 Issue 16, August, 09-13
1. Choo Q-L, Kuo G, Weiner AJ. Isolation of a DNA clonederived from a blood borne non A, non B viral hepatitis genome. Science 1989; 244: 362-4.
2. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl 1); 17-24.
3. Naoumov NV, Chokshi S, Metivier E, et al. Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. J Hepatol 1997: 27: 331-6.
4. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventive strategies. Blood Rev 2000; 14: 94-110.
5. Okamoto M, Nagata I, Murakami J, Kaji, et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery and negative anti-NS4 antibody. J Infect Dis 2000; 182: 1151-4.
6. Zaccheaus Awortu Jeremiah, Baribefe Koate1, Fiekumo Buseri, Felix, et al. Prevalence of antibodies to hepatitis C virus in apparently healthyPort Harcourt blood donors and association with blood groupsand other risk indicators. Blood Transfusion 2008; 6:150-155.
7. Caspari G, Gerlich WH, Bever J, Schmitt H. Non specific and specific anti HCV results correlated to age, sex, transaminase, Rhesus blood group and follow up in blood donors. Arch Virol 1997; 142: 473-89.
8. Busch MP, Glynn SA, Stramer SL, et al. Correlates of hepatitis C virus (HCV) RNA negativity among HCV seropositive blood donors. Transfusion 2006: 46: 469-75.